Li, Y., Wang, Y., Wang, Z., Yi, D., Ma, S.: Racial differences in three major NHL subtypes: descriptive epidemiology. cancer epidemic 39(1), 8~13(2015). https://doi.org/10.1016/j.canep.2014.12.001
Google Scholar
Swerdlow, S., Campo, E., Pileri, S., Harris, N., Stein, H., Siebert, R., et al.: 2016 revision of the World Health Organization classification of lymphomatous neoplasms. blood 127(20), 2375-2390 (2016). https://doi.org/10.1182/blood-2016-01-643569
Pacis, S., Bolzani, A., Heuck, A., Gossens, K., Kruse, M., Fritz, B., et al.: Epidemiology and practical treatment of incident diffuse large B-cell lymphoma (DLBCL): analysis of German claims data. On call. there 12(2), 293–309(2024). https://doi.org/10.1007/s40487-024-00265-8
Google Scholar
Difficult large B-cell lymphoma. Version 3.0. 5: Office of Clinical Guidelines in Cancer (2023). https://www.dmcg.dk/siteassets/kliniske-retningslinjer—skabeloner-og-vejledninger/kliniske- retningslinjer-opdelt-pa-dmcg/dlg/dlg_storcelle-diffet-b-celle-lymfom_v.3.0_admgodk051223.pdf)
Gang, A., Strøm, C., Pedersen, M., d’Amore, F., Pedersen, L., Bukhet, A.: al. R-CHOEP-14 improves overall survival in young, high-risk patients with diffuse large B-cell lymphoma compared to R-CHOP-14. Population-based survey by the Danish Lymphoma Group. Anne Oncall. 23(1), 147–153 Https://(2012). https://doi.org/10.1093/annonc/mdr058
Al-Sarayfi, D., Brink, M., Chamuleau, M., Brouwer, R., van Rijn, R., Issa, D., et al.: R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity-matched population-based study. morning. J. Hematol. 99(2), 216–222(2024). https://doi.org/10.1002/ajh.27151
Gisselbrecht, C., Glass, B., Mounier, N., et al.: Salvage therapy with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology 28(27), 4184-4190 (2010). https://doi.org/10.1200/JCO.2010.28.1618
Google Scholar
Garg, M., Takyar, J., Dhawan, A., Saggu, G., Agrawal, N., Hall, A., et al.: Diffuse large B-cell lymphoma (DLBCL): a structured literature review of epidemiology, treatment guidelines, and practice patterns of treatment. blood. 140(Supplement 1), 12106-12107 (2022). https://doi.org/10.1182/blood-2022-169045
Google Scholar
Al-Mashhadi, A., Jakobsen, L., Brown, P., Gang, A., Thorsteinsson, A., Rasoul, K., et al.: Real-world outcomes following third-line or subsequent treatment: a Danish population-based study of 189 patients with relapsed/refractory large B-cell lymphoma. Br. J. Haematol. 204(3), 839-848(2023). https://doi.org/10.1111/bjh.19201
Borchmann, P., Heger, J., Mahlich, J., Papadimitrious, M., Riou, S., Werner, B.: Healthcare resource utilization and associated costs in German patients with diffuse large B-cell lymphoma: analysis of retrospective health claims data. On call. there. 11(1), 65–81 (2023). https://doi.org/10.1007/s40487-022-00211-6
Google Scholar
Moertl, B., Dreyling, M., Schmidt, C., Hoster, E., Schoel, W., Bergwelt-Baildon, M., et al.: Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): a health economic perspective. Clinical Lymphoma Myeloma and Leukemia 22(7), 474–482(2022). https://doi.org/10.1016/j.clml.2021.12.018
Google Scholar
Trottmann, M., Blozik, E., Hilbig, M., LoVerdi, D., Pedruzzi, M., Scherer, T., et al.: Actual expenditures and survival times after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss medicine. weekly. 1533441(2023). https://doi.org/10.57187/s.3441
Google Scholar
Chacim, S., Monjardino, T., Cunha, J., Medeiros, P., Redondo, P., Bento, M., et al.: Costs, effectiveness, and safety associated with chimeric antigen receptor (CAR) T-cell therapy: results from a comprehensive cancer center. PLOS ONE 17(12), e0278950(2022). https://doi.org/10.1371/journal.pone.0278950
Gatwood, J., Masaquel, A., Fox, D., Sheinson, D., James, C., Li, J., et al.: Actual total cost of treatment by line of treatment for relapsed/refractory diffuse large B-cell lymphoma. J. Med. ikon. 27(1), 738-745(2024). https://doi.org/10.1080/13696998.2024.2349472
Google Scholar
Costa, S., Scott, D., Steidl, C., Peacock, S., Regier, D.: Real cost analysis for diffuse large B-cell lymphoma in British Columbia. Currently on call. 26(2), 108–113 (2019). https://doi.org/10.3390/cancers14040908
Huang, Q., Borra, S., Li, J., Wang, L., Shrestha, S., Sundaram, M., et al.: Time to next treatment, healthcare resource utilization, and costs associated with ibrutinib use in US veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma: a real-world retrospective. analyze. Journal of Managed Care and Specialty Pharmacy 26(10), 1266–1275 (2020). https://doi.org/10.18553/jmcp.2020.20095
Google Scholar
Cho, J., Zhang, S., Kang, D., Lee, E., Koh, H., Yun, D., et al.: Nationwide analysis of treatment patterns, survival, and medical costs of patients with relapsed or refractory diffuse large B-cell lymphoma in Korea. Front. On call. 141282323(2024). https://doi.org/10.3389/fonc.2024.1282323
Petersen, C., Jensen, K., Rosenzweig, M., von Osmanski, B., Ankarfeldt, M., Petersen, J.: Outcome and registry mapping currently used in Danish pharmacoepidemiological studies. Clean. Epidemic. 14521–542 (2022). https://doi.org/10.2147/CLEP.S341480
Google Scholar
Erlangsen, A., Fedyszyn, I.: Danish national register of public health and health-related research. Scand J Public Health 43(4), 333–339 (2015). https://doi.org/10.1177/1403494815575193
Google Scholar
Arboe, B., El-Galaly, T., Clausen, M., et al.: Danish National Lymphoma Registry: Coverage and data quality. PLOS ONE 11(6), e0157999(2016). https://doi.org/10.1371/journal.pone.0157999
Malignant Lymphoma and Cll National Annual Report: 1 January 2022 to 31 December 2022. Danish Lymphoma Database/Danish Chronic Lymphocytic Leukemia Database. National Annual Report 2022. (2022). Regional Clinical Quality Development Program (www.rkkp.dk).
Pedersen, C.: Danish Civil Registration System. Scan. J. Public. health 39(7 Supplement), 22–25 (2011). https://doi.org/10.1177/1403494810387965
Google Scholar
Lynge, E., Sandegaard, J., Rebolj, M.: Danish National Patient Registry. Scand J Public Health 39(7 Supplement), 30–33 (2011). https://doi.org/10.1177/1403494811401482
Google Scholar
Andersen, J., Olivarius, N., Krasnik, A.: Danish National Health Service Register. Scan. J. Public. health. 39(7 Supplement), 34–37 (2011). https://doi.org/10.1177/1403494810394718
Google Scholar
Kildemoes, H., Sørensen, H., Hallas, J.: Danish National Prescription Register. Scan. J. Public. health. 39(7 Supplement), 38–41 (2011). https://doi.org/10.1177/1403494810394717
Google Scholar
Hjollund, N., Larsen, F., Andersen, J.: Registration-based follow-up for social welfare and other transfer payments: Accuracy and completeness of the Danish interdepartmental administrative database compared with population-based surveys. Scan. J. Public. health. 35497–502 (2007). https://doi.org/10.1080/14034940701271882
Google Scholar
Cheson, B., Fisher, R., Barrington, S., Cavalli, F., Schwartz, L., Zucca, E., et al.: Recommendations for initial evaluation, staging, and response assessment of Hodgkin’s and non-Hodgkin’s lymphoma: Lugano classification. J. Clean. On call. 323059-3068(2014). https://doi.org/10.1200/JCO.2013.54.8800
Google Scholar
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., et al.: Long-term outcomes of patients in the LNH-98.5 trial, comparing rituximab-CHOP with standard CHOP chemotherapy in patients with DLBCL. The first randomized study to compare: a study by the groupe d’etudes des Lymphomes de l’adulte. blood 1162040~2045 (2010). https://doi.org/10.1182/blood-2010-03-276246
Sehn, L., Gascoyne, R.: Diffuse large B-cell lymphoma: optimizing outcomes in the context of clinical and biological heterogeneity. blood 125(1), 22~32(2015). https://doi.org/10.1182/blood-2014-05-577189
